Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytoreduction Surgical Procedures | 9 | 2024 | 51 | 1.990 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 455 | 1.560 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2018 | 256 | 0.770 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 1276 | 0.720 |
Why?
|
| Anastomotic Leak | 2 | 2021 | 34 | 0.720 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 25 | 0.630 |
Why?
|
| Trachelectomy | 1 | 2018 | 2 | 0.590 |
Why?
|
| Laparoscopy | 1 | 2024 | 525 | 0.560 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2020 | 199 | 0.560 |
Why?
|
| Cyanoacrylates | 1 | 2018 | 12 | 0.560 |
Why?
|
| Tissue Adhesives | 1 | 2018 | 38 | 0.550 |
Why?
|
| Fertility Preservation | 1 | 2018 | 62 | 0.540 |
Why?
|
| Genital Neoplasms, Female | 3 | 2021 | 44 | 0.490 |
Why?
|
| Colon | 1 | 2018 | 360 | 0.450 |
Why?
|
| Endometrial Hyperplasia | 1 | 2014 | 21 | 0.440 |
Why?
|
| Endometrial Neoplasms | 1 | 2014 | 110 | 0.400 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 72 | 0.380 |
Why?
|
| Neoplasm Staging | 5 | 2021 | 1322 | 0.370 |
Why?
|
| Postoperative Complications | 2 | 2021 | 3113 | 0.310 |
Why?
|
| Doxorubicin | 3 | 2021 | 300 | 0.290 |
Why?
|
| Middle Aged | 12 | 2025 | 28839 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 407 | 0.240 |
Why?
|
| Aged | 11 | 2025 | 21238 | 0.240 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 999 | 0.240 |
Why?
|
| Paclitaxel | 3 | 2021 | 134 | 0.240 |
Why?
|
| Female | 17 | 2025 | 71087 | 0.220 |
Why?
|
| Computers, Handheld | 1 | 2025 | 33 | 0.220 |
Why?
|
| Cisplatin | 3 | 2021 | 286 | 0.220 |
Why?
|
| Mitomycin | 2 | 2021 | 48 | 0.200 |
Why?
|
| Postoperative Care | 1 | 2025 | 301 | 0.190 |
Why?
|
| Patient Participation | 1 | 2025 | 244 | 0.180 |
Why?
|
| Hysterectomy | 2 | 2014 | 205 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 1356 | 0.170 |
Why?
|
| Abdominal Neoplasms | 1 | 2021 | 30 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2021 | 20 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 909 | 0.160 |
Why?
|
| Adult | 7 | 2025 | 31666 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1258 | 0.160 |
Why?
|
| Humans | 17 | 2025 | 131504 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 155 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2024 | 1450 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 393 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 741 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2025 | 5120 | 0.140 |
Why?
|
| Frailty | 1 | 2021 | 141 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2021 | 17648 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 69 | 0.140 |
Why?
|
| Surgical Oncology | 1 | 2018 | 15 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2297 | 0.140 |
Why?
|
| Tissue Adhesions | 1 | 2018 | 29 | 0.140 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 171 | 0.140 |
Why?
|
| Colonic Diseases | 1 | 2018 | 37 | 0.130 |
Why?
|
| Sutures | 1 | 2018 | 63 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 86 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 825 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 1078 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 171 | 0.130 |
Why?
|
| Random Allocation | 1 | 2018 | 421 | 0.130 |
Why?
|
| Constriction, Pathologic | 1 | 2018 | 227 | 0.130 |
Why?
|
| Gynecology | 1 | 2018 | 129 | 0.130 |
Why?
|
| Perioperative Period | 3 | 2021 | 51 | 0.130 |
Why?
|
| Intestinal Obstruction | 1 | 2018 | 86 | 0.130 |
Why?
|
| Medicare | 1 | 2020 | 435 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2024 | 6485 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 1148 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2025 | 828 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2015 | 43 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 125 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2021 | 12936 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5277 | 0.110 |
Why?
|
| Wound Healing | 1 | 2018 | 476 | 0.100 |
Why?
|
| Intestines | 1 | 2018 | 589 | 0.100 |
Why?
|
| Conization | 1 | 2013 | 5 | 0.100 |
Why?
|
| Electrosurgery | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cryosurgery | 1 | 2013 | 51 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 739 | 0.090 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 136 | 0.090 |
Why?
|
| Rats | 1 | 2018 | 3454 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 647 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6916 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6273 | 0.080 |
Why?
|
| Neoplasms | 1 | 2025 | 2969 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4684 | 0.060 |
Why?
|
| United States | 1 | 2020 | 11794 | 0.050 |
Why?
|
| Registries | 2 | 2021 | 1599 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 4037 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 80 | 0.040 |
Why?
|
| Communication | 1 | 2025 | 530 | 0.040 |
Why?
|
| Acidosis | 1 | 2021 | 99 | 0.040 |
Why?
|
| Laparotomy | 1 | 2020 | 143 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 313 | 0.040 |
Why?
|
| Young Adult | 1 | 2013 | 10092 | 0.040 |
Why?
|
| Risk Factors | 1 | 2013 | 10952 | 0.040 |
Why?
|
| Patient Selection | 1 | 2021 | 723 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1522 | 0.030 |
Why?
|
| Animals | 1 | 2018 | 34341 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 557 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Adolescent | 1 | 2013 | 20917 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 245 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 3090 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 714 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1624 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3693 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 1809 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 2205 | 0.020 |
Why?
|
| Male | 2 | 2025 | 65158 | 0.010 |
Why?
|